Olema Pharmaceuticals (OLMA) Times Interest Earned (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Times Interest Earned of -$0.63 for Q1 2026, up 97.61% year-over-year from -$0.32 in Q1 2025, and up 99.62% quarter-over-quarter from -$165.84 in Q4 2025.
Olema Pharmaceuticals (OLMA) Times Interest Earned (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Times Interest Earned for 7 consecutive years, with -$0.63 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 97.61% year-over-year to -$0.63; the TTM figure through Mar 2026 stood at -$2.2 (up 97.97% YoY), while the FY2025 annual figure was -$0.76, up 95.99% from the prior year.
- Times Interest Earned climbed to -$0.63 in Q1 2026 per OLMA's latest filing, from -$165.84 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.43 in Q3 2023 and bottomed at -$165.84 in Q4 2025.
- Historically, Times Interest Earned has averaged -$42.73 across 5 years, with a median of -$9.47 in 2022.
- Annual changes were most pronounced in 2025 — Times Interest Earned sank 17189.25% — and 2026, when it surged 97.61%.
- Olema Pharmaceuticals' Times Interest Earned stood at -$84.27 in 2022, then sank by 37.24% to -$115.65 in 2023, then decreased by 3.9% to -$120.16 in 2024, then plunged by 38.02% to -$165.84 in 2025, then jumped by 99.62% to -$0.63 in 2026.
- Business Quant data shows OLMA's Times Interest Earned at -$0.63 in Q1 2026, -$165.84 in Q4 2025, and -$147.04 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | -0.98 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.98 |
| Mar 31, 2026 | -0.63 |
| Dec 31, 2025 | -165.84 |
| Sep 30, 2025 | -147.04 |
| Jun 30, 2025 | -24.77 |
| Mar 31, 2025 | -26.42 |
| Dec 31, 2024 | -120.16 |
| Sep 30, 2024 | -0.85 |
| Jun 30, 2024 | -0.90 |
| Mar 31, 2024 | -0.84 |
| Dec 31, 2023 | -115.65 |
| Sep 30, 2023 | -0.43 |
| Jun 30, 2023 | -0.68 |
| Mar 31, 2023 | -14.59 |
| Dec 31, 2022 | -84.27 |
| Sep 30, 2022 | -7.26 |
| Jun 30, 2022 | -9.47 |
| Mar 31, 2022 | -6.62 |
| Dec 31, 2021 | -1.03 |
| Sep 30, 2021 | -0.25 |